Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease

Jose L. Martinez1,2, Matthew D. Zammit2,3, Nicole R. West1,2, Bradley T. Christian2,3,4 and Anita Bhattacharyya2,5*

1 Cellular and Molecular Biology Graduate Program, University of Wisconsin, Madison, WI, United States, 2 Waisman Center, University of Wisconsin, Madison, WI, United States, 3 Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States, 4 Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States, 5 Department of Cellular and Regenerative Biology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States

Down syndrome (DS, trisomy 21) is characterized by intellectual impairment at birth and Alzheimer’s disease (AD) pathology in middle age. As individuals with DS age, their cognitive functions decline as they develop AD pathology. The susceptibility to degeneration of a subset of neurons, known as basal forebrain cholinergic neurons (BFCNs), in DS and AD is a critical link between cognitive impairment and neurodegeneration in both disorders. BFCNs are the primary source of cholinergic innervation to the cerebral cortex and hippocampus, as well as the amygdala. They play a critical role in the processing of information related to cognitive function and are directly engaged in regulating circuits of attention and memory throughout the lifespan.

Given the importance of BFCNs in attention and memory, it is not surprising that these neurons contribute to dysfunctional neuronal circuitry in DS and are vulnerable in adults with DS and AD, where their degeneration leads to memory loss and disturbance in language. BFCNs are thus a relevant cell target for therapeutics for both DS and AD but, despite some success, efforts in this area have waned. There are gaps in our knowledge of BFCN vulnerability that preclude our ability to effectively design interventions. Here, we review the role of BFCN function and degeneration in AD and DS and identify understudied aspects of BFCN biology. The current gaps in BFCN relevant imaging studies, therapeutics, and human models limit our insight into the mechanistic vulnerability of BFCNs in individuals with DS and AD.

Keywords: basal forebrain cholinergic neurons, down syndrome, Alzheimer’s disease, pluripotent stem cell, neurodegeneration

INTRODUCTION

Down syndrome (DS, trisomy 21, T21) is a complex developmental disorder that arises from trisomy of human chromosome 21 (Hsa21) (Lejeune et al., 1959) and is both a neurodevelopmental and a neurodegenerative disorder. Intellectual disability in individuals with DS ranges from mild to moderate with deficits in specific domains, including attention and memory. DS features arise as a result of uncharacteristic dosage of coding and non-coding sequences found on Hsa21. Despite
its known cause and high incidence (Shin et al., 2009; Presson et al., 2013; de Graaf et al., 2015), little is known about the underlying developmental defects and degenerative outcomes that cause the characteristics of DS.

Down syndrome is also characterized by Alzheimer's disease (AD) pathology that emerges in middle age (Scott et al., 1983; Coyle et al., 1986; Visser et al., 1997; Burt et al., 1998; Menendez, 2005; Head et al., 2012; Snyder et al., 2020). The prevalence of dementia in individuals affected by DS increases with each consecutive decade: 9% between the ages of 45 and 59 years, 18% between 50 and 54 years, and 32% between 55 and 59 years with a cumulative risk of 90% by age 65 (Zigman et al., 1996; Holland et al., 2000; Head et al., 2016; Sinai et al., 2018). In addition, the prevalence of symptomatic AD in individuals with DS reaches 90–100% by age 70, while only 11.3% of the general population have AD by the age of 65 (Fortea et al., 2020; Alzheimer’s Association, 2021). Additionally, there are sex differences, with DS males developing AD-like pathology at an earlier age than females (Zigman et al., 1996; Holland et al., 2000; Head et al., 2012). Thus, although the onset of dementia and AD in DS is beginning to be defined, it is not known what triggers the pathology nor what the earliest events in AD in DS are.

Basal forebrain cholinergic neurons (BFCNs) are a vulnerable population of neurons in both DS and AD (Yates et al., 1980; Beyreuther and Masters, 1995; Salehi et al., 2004; Baker-Nigh et al., 2015; Chen et al., 2018). BFCNs provide the primary source of cholinergic innervation to the cerebral cortex, hippocampus, and amygdala, and play a critical role in the processing of information related to cognitive function, as they are directly engaged in regulating circuits of attention and memory (Mesulam et al., 1983a; Woolf, 1991; Ballinger et al., 2016). BFCNs degenerate during aging and cell loss correlates with memory loss in old age and in individuals affected by AD (Mori, 1997; White and Ruske, 2002; Mandas et al., 2014). In DS, fewer BFCNs suggest faulty development or increased degeneration as a hallmark of reduced cognition (Casanova et al., 1985). The critical role of BFCNs in cognition, as well as their susceptibility in both DS and AD, provide a clear link to the cognitive decline in both DS and AD.

BFCNs ARE IMPORTANT IN AD AND DS

BFCNs Are a Unique Population of Neurons

Basal forebrain cholinergic neurons are a cluster of large neurons in the basal forebrain first described by Meynert (1872) and termed the “magnocellular basal forebrain system” (Hedreen et al., 1984) or the nucleus basalis of Meynert (NbM) in primates (Koelliker, 1896). Unlike other neuronal types, whose nuclei of origin are easy to identify, BFCNs often form dense clusters with no easily identifiable borders to justify the identification of a nucleus. Cholinergic neurons have extremely long and complex processes with a single human neuron having an estimated arborization length of >100 m (Wu et al., 2014). BFCNs express several neurotransmitter receptors that include adrenergic, glutamatergic, GABAAergic, estrogen receptors, and endocannabinoids (Miettinen et al., 2002; Harkany et al., 2003; Mufson et al., 2003; Zaborszky et al., 2004; De Souza Silva et al., 2006). Their neuronal projections extend to the cerebral cortex, hippocampus, and amygdala and are the primary source of innervations to the cortex. Unlike primary sensory cortical neurons, cholinergic neurons remodel their axonal arborizations and synapses continually through the lifespan (Sarter et al., 2003; Hasselmo, 2006; Botly and De Rosa, 2009; Heys et al., 2010; Mitsushima et al., 2013; Schmitz and Duncan, 2018).

Basal forebrain cholinergic neurons are classified based on their projection targets defined in rats and non-human primates (Mesulam et al., 1983a,b; Butcher and Semba, 1989; Coppola and Disney, 2018; Solari and Hangya, 2018). Ch1 and Ch2, neurons from the medial septum and the vertical limb of the diagonal band, are the primary source of cholinergic innervation to the hippocampus. Neurons from the horizontal limb of the diagonal band, Ch3, connect to the olfactory bulb, piriform, and entorhinal cortices. These regions act as a network hub for memory, as they are the interface between the hippocampus and neocortex. Neurons in the substantia innominata/nucleus basalis, Ch4, project to the basolateral amygdala and innervate the entire neocortex. Ch1, Ch2, and Ch3 also project to orexin/hypocretin neurons in the lateral hypothalamus region of the brain (Sakurai et al., 2005). The orexinergic nucleus neurons project throughout the nervous system to mediate cognition and various physical processes (Chieffi et al., 2017). The ratio of cholinergic to non-cholinergic neuronal projections in each of these target areas varies and may affect functional connectivity. On average, the ratio is lower in the frontal area (0.3) and higher in the posterior area (0.6) (Zaborszky et al., 2015). Through this complexity, BFCNs regulate attention, memory, learning, and processing of information related to cognitive function, and so deficits in BFCN number or function can negatively impact an individual’s spatial reasoning, language, and cognition.

BFCNs in Aging and AD

Basal forebrain cholinergic neuron dysfunction or degeneration is implicated as a driving factor for disease in a diverse range of human neurocognitive conditions and neuropsychiatric disorders including Parkinson’s disease (PD), schizophrenia, drug abuse, and AD (Détári, 2000; Conner et al., 2003; Blanco-Centurion et al., 2007; Weinberger, 2007; Jones, 2008; Kaur et al., 2008; Lin and Nicolelis, 2008; Parikh and Sarter, 2008; Goard and Dan, 2009). Strong correlation between the thinning of the Ch4 BFCNs and mild cognitive impairment of PD patients (Rong et al., 2021) suggests that loss of BFCNs contributes to the cognitive decline in PD. BFCN expression of histamine H1 receptor (H1R) is decreased in patients with schizophrenia that show negative symptoms and hallmarks of schizophrenia, such as the formation of sensorimotor gating deficit, social impairment, and anhedonia-like behavior (Cheng et al., 2021). Deleting the H1R gene in BFCNs in mice is sufficient to elicit these negative symptoms.
Degeneration of cholinergic neurons in the basal forebrain is strongly correlated with cognitive function. It is not known what causes the degeneration of BFCNs. Several hypotheses have been raised to define the mechanisms underlying BFCN degeneration in DS and AD including those focused on acetylcholine, amyloid-β, tau, inflammation, and retrograde transport (Figure 1). Yet, gaps in our understanding of their role specifically in BFCNs remain.

Cholinergic Hypothesis

Because the cholinergic system is important in various forms of dementia, including AD (Davies and Maloney, 1976; Whitehouse et al., 1982; Price et al., 1986; Mufson et al., 1989; Perry et al., 1992; Bierer et al., 1995; Mufson et al., 1995; Ballinger et al., 2016), the use of choline acetyltransferase inhibitors to reverse cholinergic hypofunction in AD has been shown to facilitate memory function, albeit to a moderate degree (Ferreira-Vieira et al., 2016). The cholinergic neuronal loss in the basal forebrain is observed not only in AD, but also in PD, DS, Huntington’s disease, and other neurocognitive diseases (Aquilonius et al., 1975; Yates et al., 1980; Arendt et al., 1983; Dubois et al., 1983; Barron et al., 1987; Ferrante et al., 1987; Kato, 1989). Studies have demonstrated that cholinergic synapses are affected by amyloid-β oligomers, and this neurotoxicity is the major contributor to cognitive impairment in AD and DS (Terry et al., 1991; Selkoe, 2002; Selkoe and Hardy, 2016). These data and others led to the “cholinergic hypothesis of AD” (Coyle et al., 1983; Contestabile, 2011; Dumas and Newhouse, 2011). As discussed later, this hypothesis has fallen out of favor, but recent data should serve to revise studies on this critical system.

Amyloid-β Cascade Hypothesis

The amyloid-β cascade hypothesis was advanced by the finding of a pathogenic mutation in the APP gene (encoded on Hsa21), which indicated that APP metabolism and amyloid-β deposition were the primary events in AD (Hardy and Allsop, 1991; Selkoe, 1991). APP is cleaved by two different proteolytic processes: the amyloidogenic (β pathway, pathogenic) that results in production of insoluble amyloid-β and the non-amyloidogenic (α pathway, non-pathogenic) pathway (Liu et al., 2019) that does not produce insoluble amyloid-β. It is well established that high concentrations of amyloid-β protein are neurotoxic to neurons, causing atrophy of the axons and dendrites leading to neuronal death (Yankner et al., 1990). Normally the small amount of amyloid-β that is produced via the β pathway is cleared by the immune system, but APP mutations such as Lys670Asn/Met671Leu (Swedish) can direct more amyloidogenic proteolysis (Yan and Vassar, 2014; Zhou et al., 2018). Similarly, individuals with a rare familiar trait known as duplication of APP (Dup-APP), also develop early onset AD (Rovelet-Lecrux et al., 2006, 2007; Sleeegers et al., 2006; Kasuga et al., 2009; Thonberg et al., 2011; Hoel et al., 2012; McNaughton et al., 2012; Swaminathan et al., 2012; Wiseman et al., 2015). Thus, APP and amyloid-β have a causative role in AD.

The additional copy of Hsa21-encoded APP in DS may be a driving factor for the emergence of AD in individuals with DS by increasing amyloid-β. Likewise, individuals with a partial trisomy of chromosome 21 that lack an additional copy of APP do not develop AD (Prasher et al., 1998; Korbel et al., 2009). While these data suggest a key role of APP in the development of AD in DS, recent studies from DS models show the important role of APP in the amyloidogenic aspects of AD but challenge the notion that increased APP levels are solely responsible for DS-associated
AD pathogenesis (Wiseman et al., 2015, 2018; Ovchinnikov et al., 2018). Additional genes on Hsa21 may regulate the course of AD in DS individuals, but further work is required to elucidate their role and importance.

**Tau Propagation Hypothesis**
The tau propagation hypothesis focuses on the appearance of neurofibrillary tangles (NFTs) and misfolded tau that propagates through the brain in a prion-like way, eventually spreading throughout the brains of AD patients (Frost et al., 2009). Tau proteins stabilize the microtubules that act as a highway for the transportation of cargo in dendrites and axons (Clavaguera et al., 2009; Frost et al., 2009). Tau is encoded by approximately 352 residues and alternative splicing of exons 2, 3, and 10 results in six isoforms. The balance between isoforms regulates cellular processes (Goedert et al., 1989; Andreadis et al., 1992). An equilibrium between two isoforms (3R and 4R) may be important in preventing the formation of tau aggregates, a common feature in AD pathology. Hyperphosphorylated tau proteins form helical filaments, which aggregate to form NFTs (Grundke-Iqbal et al., 1986; Kosik et al., 1986; Nukina and Ihara, 1986), a pathological feature of AD (Braak and Braak, 1996; Braak et al., 1999).

Individuals with DS show the formation of NFTs as early as 30 years of age (Lott and Head, 2019; Perez et al., 2019; Gomez et al., 2020). Tau phosphorylation and the appearance of NFTs in DS may be regulated by two Hsa21 genes, APP and DYRK1A. DYRK1A phosphorylates APP at the Thr668 residue, which leads to an increase in activated APP. The resulting p-APP phosphorylates the Thr212 residue of tau, resulting in pTau that is implicated in AD pathology (Alonso et al., 2010, 2018). A biomarker study revealed that individuals with DS had decreased amyloid-β over time, while the plasma level of tau and NFT increased leading to a reduction in basal forebrain volume (Mengel et al., 2020; Schmitz et al., 2020). Thus, in addition to APP, tau phosphorylation may be dysregulated in DS and specifically in BFCNs.

**Inflammation Hypothesis**
Inflammation occurs in the brains of individuals with AD and DS patients as a response to neuritic plaques and NFTs (Wilcock, 2012). The inflammatory response is predominantly mediated by microglial cells, brain-specific macrophages in the central nervous system (CNS) that make up about 15% of all brain cells (Clayton et al., 2017). Microglial inflammatory responses have been identified as potentially playing an important role in the development of AD pathology (Clayton et al., 2017; Kinney et al., 2018; Chen and Mobley, 2019). In AD patients a two to five-fold increase in the concentration of aggregated microglia near neurons with NFTs may indicate higher activity of microglial cells in AD (Calsolaro and Edison, 2016). Amyloid-β has a synergistic effect with the cytokine activation of microglia (Meda et al., 1995). It is through the CD36-TLR4-TLR6 receptor complex and the NLRP3 inflammatory complex that amyloid-β can bind to microglia cells, release inflammation factors and
elicit immune responses (Heneka et al., 2013; Sheedy et al., 2013). Levels of inflammatory factors such as TNF-α, IL-1β, TGF-β, IL-12, and IL-8 correlate with AD and increased levels in the CNS have also been implicated in increased damage in brains of AD patients (Michaud et al., 2013). Biomarkers in DS plasma show consistently higher levels of amyloid-β and IL-1β (Startin et al., 2019). Similarly, in DS, IL-1β and TGF-β induce Hsa21 proteases ADAMTS1 and ADAMTS5 in the CNS. The ADAMTS proteins are of interest because they are involved in neurodegeneration (Gurses et al., 2016). Inflammation likely plays a major role in AD in DS, but the mechanism is currently under investigation. Additionally, it is not clear whether BFCNs are affected by inflammation.

**Retrograde Transport**

Basal forebrain cholinergic neurons depend on nerve growth factor (NGF) and brain derived neurotrophic factors (BDNF) for their survival and function (Fahnestock and Shekari, 2019). Both neurotrophic factors are retrogradely transported from BFCN targets. The precursor for NGF (proNGF; pNGF) binds to the NGF receptors TrkA and p75NTR, binding with higher affinity to p75NTR while mature NGF binds more strongly to the TrkA receptor (Fahnestock and Shekari, 2019). BFCNs express both receptors, which are activated by pNGF to elicit TrkA-dependent pathways of survival and growth through MAPK and Akt-mTOR. However, inactivation or imbalance of TrkA leads to activation of p75NTR-dependent apoptotic pathways, such as JNK. TrkA is also increasingly lost in mild cognitive impairment and AD (Fahnestock and Shekari, 2019). Studies modeling aging with embryonic rat basal forebrain neurons in culture have shown the axonal transport of NGF and BDNF are impaired with age, suggesting a vulnerability of BFCNs in aging as well as in age-related disorders such as AD (Budni et al., 2015).

In DS, it has been speculated that the additional copy of APP on Hsa21 has a downstream impact on the retrograde transport of neurotrophins. Using mouse models, overexpression of APP hyperactivates Rab5, a key regulator of endosome fusion and trafficking, leading to abnormally large endosomes, which normally carry the NGF signal retrogradely (Xu et al., 2016). There are two explanations as to how hyperactivation of Rab5 impairs neuronal trophic signaling. First, the enlarged Rab5 endosomes may have a difficult time moving retrogradely within the axon, thus resulting in a net decrease in NGF delivery to the soma (Xu et al., 2018). Alternatively, the increase Rab5 activation can promote premature delivery of trophic signals to late endosomes/lysosomes, resulting in early degeneration of NGF/TrkA signaling (Zhang et al., 2013; Xu et al., 2018). Both of these possibilities would lead to decreased trophic signaling and support of BFCNs, resulting in neuronal death. No studies have assessed retrograde transport in human DS BFCNs and so we do not know whether similar mechanisms are in play.

Here, we summarize the predominant mechanisms that have been raised that may underlie specifically BFCN pathology. However, other characteristics of T21 cells may also be important in BFCN pathology. For example, oxidative stress has long been implicated in DS (Lott et al., 2006; Perluigi and Butterfield, 2012) and, in fact, treatment of aged Ts65Dn mice with vitamin E reduced oxidation levels and decreased cholinergic neuron pathology in the basal forebrain (Lockrow et al., 2009). Human studies are needed to test whether these results translate to humans.

It is also possible deficient autophagy contributes to BFCN pathology (Colacurcio et al., 2018). Assessment of human T21 cortical neurons has recently emerged (Botté et al., 2020) and so it will be important for future studies to define vesicle trafficking in BFCNs as well as cortical neurons.

**IMAGING REVEALS VULNERABILITY OF BFCNS IN AD AND DS**

Although there are multiple vulnerable populations of neurons in various brain regions, the classic model of AD pathology progression postulates that the initial accumulation of pTau, and later amyloid-β accumulation, in the entorhinal cortices leads to the degeneration process that spreads to the temporoparietal cortex over time in a stage-like fashion (Braak and Braak, 1991; Thal et al., 2002; Fernandez and Lopez, 2020). Imaging studies of AD models support this hypothesis, as they indicate that the accumulation of pTau and amyloid-β in certain brain regions reflect the local neural vulnerability that spreads over time (Davies and Maloney, 1976; Whitehouse et al., 1981; Arendt et al., 1985; Mesulam et al., 2004; Mattson and Magnus, 2006; Geula et al., 2008; Braak and Del Tredici, 2011; Saxena and Caroni, 2011; Khan et al., 2014; Baker-Nigh et al., 2015; Grothe et al., 2018; Sepulcre et al., 2018; Hanseeuw et al., 2019). Yet, recent imaging studies have started to challenge this model. A longitudinal study using cerebrospinal fluid (CSF) and MRI data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) identified neurodegeneration of the NbM in abnormal and normal groups defined by previously validated CSF pTau/amyloid-β ratios (Fernandez-Cabello et al., 2020). Two non-overlapping and well powered data sets from the ADNI, along with whole-brain regression models show that the relationship between NbM volumes and neurodegeneration is specific to regions of the entorhinal cortex and the perirhinal cortices (Fernandez-Cabello et al., 2020). These results suggest a model in which amyloid-β pathology in the ascending BFCN projections from NbM first spreads to the entorhinal cortex and then to the temporoparietal neurodegeneration typically attributed to the earliest stages of AD. The degeneration of the BFCN projection system as an early event in AD pathology highlights the susceptibility of these neurons to early pathology and later downstream impacts on other vulnerable populations, challenging the current notion that the entorhinal cortex is upstream of this event. There is a clear need for additional studies exploring the initial events in AD pathology to better understand the early disease stage vulnerable populations.

There are limited human studies in DS that focus on BFCNs as a vulnerable neuronal population, highlighting the critical need for more neuropathological and imaging studies. However, within the last several years, large studies using positron emission tomography (PET) to characterize the preclinical progression of AD in DS have emerged using the AT(N)
(amyloid/tau/neurodegeneration) disease research framework (Jack et al., 2018; Fortea et al., 2020; Rafii et al., 2020). Furthermore, no DS studies with PET focus on imaging of BFCNs during preclinical AD. The Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS) is an ongoing longitudinal study aimed to better understand AD progression in DS by characterizing AD biomarker change in one of the world's largest DS research cohorts (Handen et al., 2020). With PET imaging, a pattern of early and prominent amyloid-β retention was identified in the dorsal and ventral striatum (Handen et al., 2012); a pattern which has also been observed in other forms of early-onset AD (Klunk et al., 2007; Remes et al., 2008; Vilemagne et al., 2009; Bateman et al., 2012). Apart from the striatum, the cortical retention of amyloid-β in DS has an identical pattern to late-onset AD, with amyloid-β increasing at longitudinal rates of 3–4% annually (Lao et al., 2017; Tudorascu et al., 2019; Zammit et al., 2020a, 2021).

Imaging of NFTs with PET is a more recent addition to the field of AD research, but its use in DS is very limited. Through the Down Syndrome Biomarker Initiative, an early DS study with a relatively small sample size demonstrated that increased NFT burden was highly associated with cognitive impairment (Rafi et al., 2017). A study from the ABC-DS with a large sample size identified that NFT retention in DS conforms to the conventional Braak staging of NFT pathology, with the earliest evidence of NFTs in the entorhinal cortex and hippocampus (Tudorascu et al., 2020). NFT PET studies in DS have also been limited to cross-sectional analyses, and longitudinal measurements are needed to characterize the annual rates of NFT progression and the latency period between the onset of amyloid-β and NFTs. PET imaging of glucose metabolic change is also envisioned as a proxy measurement for neurodegeneration in DS.

In DS, glucose hypometabolism has been observed with local increases in amyloid-β throughout regions implicated in AD (Lao et al., 2018). Glucose hypometabolism in the frontal cortex, anterior cingulate, posterior cingulate, parietal cortex, precuneus, and temporal cortex were also highly associated with worsening cognitive performance evaluated using measures of episodic memory (Zammit et al., 2020b), which have been validated as sensitive indicators of the transition between preclinical and prodromal AD in DS (Hartley et al., 2020). In addition, PET measurement of glucose metabolism was capable of distinguishing cases of MCI-DS and AD from cognitively stable DS, suggesting it as a sensitive marker of neurodegeneration (Zammit et al., 2020b). Increased imaging of AD has shown the progression of biomarkers between DS and late-onset AD are very similar, but future studies would require close examination of BFCNs in vivo to identify the link between AD biomarkers and BFCN degeneration.

**INTERVENTIONS FOR AD AND DS**

Current FDA approved pharmacological interventions for AD are limited. There are five approved AD medications; donepezil, galantamine, rivastigmine, memantine, and a combination of donepezil and memantine (Alzheimer's Association, 2019). Donepezil, galantamine, and rivastigmine are acetylcholinesterase inhibitors, while memantine is a non-competitive low-affinity NMDA receptor open-channel blocker that also affects glutamatergic transmission (Yiannopoulou and Papageorgiou, 2020). Recent work has focused on designing experimental drugs targeting specific points of the pathophysiological mechanism of AD that include amyloid-β, p-Tau metabolism, mitochondrial dysfunction, oxidative stress, and inflammation. Most, if not all, have proven clinically unsuccessful, with Donepezil being the last FDA approved AD drug in 2010. It is important to note that most of the AD drugs are acetylcholinesterase inhibitors that reduce the breakdown of acetylcholine released from BFCNs. Much like donepezil, galantamine works by inhibiting acetylcholinesterase in a reversible and selective manner while rivastigmine is a pseudo-irreversible inhibitor of both acetylcholinesterase and butyrylcholinesterase. These inhibitors can mitigate the memory deficits associated with aging and AD (Rusted, 1994; van Reekum et al., 1997; Du et al., 2018). However, their effects appear to be transient, as they only show efficacy during the first year of administration, with further memory decline occurring later. In the AD2000 study, a large “real life” trial on the impact of regular use of donepezil, AD patients treated with donepezil did not show significant benefits compared to placebo in progression of disability at 3 years of treatment, rendering this approach a symptomatic relief with marginal benefits (Bentham et al., 2004; Du et al., 2018). These results led to the cholinergic hypothesis and targeting of the cholinergic pathway falling out of favor in the AD research community (Cacabelos, 2007). Yet, it is clear that the cholinergic system is of high importance in AD and DS and that BFCNs remain a relevant cell population and potential therapeutic target.

Despite the prevalence of AD in DS patients, individuals with DS have been traditionally excluded from most clinical trials of anti-dementia drugs (Strydom et al., 2018). Cholinergic therapies have been advocated for DS to ameliorate dysfunctional neuronal circuity (Kishnani et al., 2001). The available AD-related pharmacologic therapies offer minimal usefulness in symptom reduction and fail to stop or slow down disease progression (Areosa and Sherriff, 2003; Cacabelos, 2007; Folch et al., 2018; Tayebati et al., 2019). Yet, combined treatment with cholinesterase inhibitors and memantine have also been used to ameliorate both cognitive and behavioral issues in AD and DS. A longitudinal study of 310 people with DS and AD indicated that those undergoing cholinesterase inhibitor treatment had comparable outcomes, improved cognition and behavior, to those with sporadic AD (Eady et al., 2018). More interestingly, individuals with DS treated with either a single cholinesterase or in combination had a median survival rate of ~5.6 years after diagnosis, an improvement compared to those who did not take medication who had a median survival rate of ~3.4 years (Eady et al., 2018). Not only did these results show that modulating the cholinergic system can improve cognition, but it can also have a significant impact on the length of survival for DS individuals diagnosed with AD. Thus, the cholinergic system and BFCNs in particular warrant further investigation as a potential therapeutic target in DS.
In addition to the FDA approved medications for AD, additional experimental therapies are being considered to ameliorate cognitive decline or AD onset in DS. Inspired by improvement and protective mechanisms against neurodegeneration in Caenorhabditis elegans models of PD, treatment of DS induced pluripotent stem cell (iPSC)-derived neurons with N-butylidenephthalide reduced amyloid-β aggregates and NFTs (Chang et al., 2015). This amyloid-β scavenger is a promising therapy to target the proteopathy of AD that leads to BFCN deficits. Rapamycin rescues molecular pathways associated with abnormal mTOR phosphorylation and ameliorates the rate of neurodegeneration in DS mouse models, improving their cognition (Tramutola et al., 2018). Lastly, the use of Fluoxetine, a widely used antidepressant, in a DS mouse model at an early postnatal age showed promise in increasing neurogenesis and reducing learning deficits (Guidi et al., 2013). However, further human studies focused on BFCNs are needed, as this field heavily relies on animal models.

**MODELING AD IN DS AND BFCNs**

**Mouse Models: Do They Recapitulate BFCN Pathology?**

Mouse models of DS enable experimental approaches that are not feasible in humans, such as the study of disease progression in a regulated environment, intervention trials, validation of imaging results, and also permit gene-gene interaction studies of Hsa21-specific DS genes (Hamlett et al., 2016; Herault et al., 2017). Of the 225 protein coding genes found on Hsa21, 166 are conserved in three regions in mice, murine (mmu) chromosome 10, 16, and 17 (Hattori et al., 2000; Akeson et al., 2001). Mouse models of DS have provided evidence of the influence of individual genes on Hsa21 that lead to deficits in BFCNs (Kiss et al., 1989; Sweeney et al., 1989; Coyle et al., 1991; Cooper et al., 2001; Hunter et al., 2004; Salehi et al., 2006; Ash et al., 2014; Kelley et al., 2014a, 2019; Powers et al., 2016, 2017).

The vast majority of the aging and AD studies in DS have been conducted on the Ts65Dn mouse, the prevalent model of DS for many years (Davisson et al., 1993; Reeves et al., 1995). Developed in the early 1990s by Muriel Davisson, this model contains 120 orthologs of Hsa21 protein encoding genes via a segmental trisomy of mmu 16 (Davisson et al., 1993). The aneuploidy in the Ts65Dn mouse is not lethal as in the Ts16 mouse model, but their lifespan is shorter than diploid mice (Sanders et al., 2009). However, 25% of trisomic genes in Ts65Dn are not Hsa21 orthologs, and 45% of Hsa21 orthologs are not trisomic (Zhao and Bhattacharyya, 2018). Thus, the Ts65Dn model has genetic limitations as an age-related DS and AD pathology model. Nonetheless Ts65Dn mice do show several relevant deficits including progressive memory decline, hippocampal abnormalities, increased APP production, and adult-onset degeneration of BFCNs, locus coeruleus neurons, and noradrenergic cortical innervations (Hamlett et al., 2016). Sex differences have been described in the Ts65Dn model; female Ts65Dn mice show a decrease in BFCN number as well as a smaller NbM region area as compared to males by 34 and 20%, respectively (Kelley et al., 2014b). No human studies have assessed sex differences in BFCNs and so we do not know how well these results translate to humans.

Similar to the Ts65Dn model, the Ts1Cje mouse model shows many relevant phenotypes including abnormalities in learning, memory, and synaptic plasticity (Gardiner et al., 2003). The Ts1Cje model contains a shorter Mmu16 trisomy than the Ts65Dn mouse, and the Ts2Cje model, whose chromosomal rearrangement of the Ts65Dn genome caused a translocation to Mmu12 forming a Robertsonian chromosome, show similar phenotypes to Ts65Dn. Both Ts1Cje and Ts2Cje mice exhibit oxidative stress, tau hyper-phosphorylation, mitochondrial dysfunction, and show some learning and memory deficits, and ultimately BFCN degeneration similar to the processes identified in Ts65Dn mice (Hamlett et al., 2016).

MSTI Ts65 mouse models of DS contain only a small fragment of Hsa21 orthologs in comparison to other models (Duchon et al., 2011). They contain approximately 33 orthologs of Hsa21 genes within the genetic segment ranging from APP to Sod1 (Sago et al., 1998). With complete trisomy of all Hsa21 syntenic regions, the Mmu10−Dp(10)1Yey/+ (Ts1Yey), Mmu17−Dp(16)1Yey/+ (Ts2Yey), and Mmu16−Dp(17)1Yey/+ (Ts3Yey) triple aneuploid mouse model is the most complete model of DS to date (Li et al., 2007; Yu et al., 2010). Ts3Yey mice have similar brain morphology to Ts65Dn mice and confirm the genetic basis for behavioral and morphological phenotypes, thus offering promise for developing more appropriate and complete mouse models for DS in the future (Duchon et al., 2011; Hamlett et al., 2016).

Basal forebrain cholinergic neuron neuropathology is apparent in Ts65Dn mouse models of AD in DS. Age-related degeneration starts around 6–8 months of age, with significant BFCN cell body atrophy at 6 months and major loss at age 8 and 10 months (Contestabile et al., 2006; Hamlett et al., 2016). In addition, major deficits in both choline acetyltransferase (ChAT) and NGF receptor TrkA in BFCNs are detectable at these ages (Contestabile et al., 2006). At a later age, increased neurochemical markers, including inflammatory markers and APP cleavage products, suggest continual progression of AD neuropathy in Ts65Dn mice (Contestabile et al., 2006). Although this study highlights the critical role of BFCNs in the progression of AD in DS, it is crucial to develop both animal and human models that capture the full trisomy in DS to better study this neuropathology.

Targeting the cholinergic pathway as a therapeutic strategy has been carried out in Ts65Dn mice. Maternal choline supplementation and gene expression analysis of laser capture microdissection (LCM)-captured CA1 pyramidal neurons in maternal choline supplemented Ts65Dn mice offspring at 6 months (prior to BFCN degeneration) and 11 months (post BFCN degeneration) of age had improved spatial and recognition memory task performance as compared to...
their littermate controls (Lockrow et al., 2011), highlight the importance of cholinergic levels in DS for healthy neural circuits (Alldred et al., 2018, 2019). Memantine treatment in these mice resulted in increased expression of the neurotrophic factor BDNF in the frontal cortex and hippocampus (Lockrow et al., 2011). Thus, mouse models of DS provide proof of principle that cholinergic therapies may be successful.

**Human Models**

The incomplete genetic recapitulation of Hsa21 in mouse models, and trisomy of non-Hsa21 orthologs, likely influences the effects of orthologous Hsa21 genes and, more importantly, may cause genetic consequences and downstream cellular and behavioral characteristics that are not relevant to DS. Thus, there is need for analysis of human cells from individuals with DS to have complete trisomy of Hsa21 (Herault et al., 2017; Zhao and Bhattacharyya, 2018). In addition, the failures of clinical trials in AD for therapeutic targets based on mouse models argues for the use of human patient-derived cells in target identification and drug screening.

The discovery of reprogramming factors to generate iPSCs from adult somatic cell types opened the doors to derive PSCs from individuals with specific genetic and non-genetic disorders, including DS (Thomson et al., 1998; Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008b). iPSCs can model human neural development by mimicking in vivo spatial and temporal cues during brain development in vitro (Tao and Zhang, 2016) and enable the establishment of functionally specialized neural subtypes (Park et al., 2008a; Chou et al., 2012; MacLean et al., 2012; Mou et al., 2012; Briggs et al., 2013; Jiang et al., 2013; Lu et al., 2013; Weick et al., 2013; Chen et al., 2014; Pipino et al., 2014; Huo et al., 2018). iPSCs are thus a useful model system to study DS and AD (Li et al., 2012; Murray et al., 2015; Ovchinnikov et al., 2018; Real et al., 2018).

Isogenic control iPSCs are important research tools to distinguish the consequences of T21 from human genetic variation. The generation of isogenic euploids can result from culture-induced spontaneous loss of the extra Hsa21 (Park et al., 2008a; MacLean et al., 2012). Alternatively, 2–4% of DS cases are mosaic individuals in which their somatic cells are mosaic for T21 (Papavassiliou et al., 2009; Murray et al., 2015). By taking advantage of cellular mosaics, isogenic T21 and euploid iPSCs can be derived from the same individual (Weick et al., 2013; Murray et al., 2015; Gough et al., 2020).

Isogenic cells can be generated by inducing chromosome loss (Real et al., 2018). In addition, various methods have been used to genetically correct the gene dose of the T21 by eliminating or selectively mutating specific genes. Alternatively, others have taken a candidate gene approach to selectively reduce the gene dose using CRISPR/Cas9-mediated gene manipulation (Park et al., 2008a). Full chromosomal correction of the gene dose imbalance has been accomplished using XIST-mediated (Jiang et al., 2013) or TKNEO-mediated silencing of the trisomic chromosome in iPSCs (Li et al., 2012) and ZSCAN-induced elimination of the extra chromosome (Amano et al., 2015). These strategies may enable elucidation of the genetic and cellular consequences of T21.

**iPSC to BFCN**

Much of the research done using T21 iPSCs derived from individuals with DS has been to understand cortical development and pathology (Weick et al., 2013; Huo et al., 2018; Real et al., 2018). T21 iPSC-derived cortical neurons showed impairment in synaptic activity, as well as compensatory responses to oxidative stress (Shi et al., 2012; Briggs et al., 2013; Weick et al., 2013; Sobol et al., 2019).

Little work has been done to model BFCNs with iPSCs in DS and AD. Basal forebrain neurons (including BFCNs and GABAergic interneurons) originate in neurogenic areas of the most ventral regions of the telencephalon, the medial ganglionic eminences (MGE) and preoptic area (POA) (Sussel et al., 1999; Brazel et al., 2003). Patterning of the MGE is dependent on a sonic hedgehog (SHH) signaling gradient for ventralization of the neural tube (Xu et al., 2005; Gulacsi and Anderson, 2006; Li et al., 2009). MGE progenitors express the transcription factor NKKX2.1, whose expression is regulated by SHH (Du et al., 2008; Xu et al., 2008, 2010). Despite the known development of BFCNs from the MGE, few differentiation protocols have been established to generate BFCNs from iPSCs...
(Bissonnette et al., 2011; Liu et al., 2013a; Duan et al., 2014; Hu et al., 2016), and many result in mixed populations of cells. The most robust technique (Liu et al., 2013a; Hu et al., 2016) relies on an initial ventralization patterning with SHH and addition of NGF to allow for the survival, differentiation and maturation of BFCN and yields ~90% progenitors expressing NKX2.1. Moreover, ~40% of NKX2.1+ cells co-express OLIG2 and ~15% of NKX2.1+ cells also express ISLET1, which are ventral markers and are both important for BFCN development (Wang and Liu, 2001; Furusho et al., 2006). Approximately 40% of the resulting neurons express ChAT, the enzyme responsible for biosynthesis of the neurotransmitter acetylcholine and a mature BFCN marker (Hu et al., 2016; Figure 2).

Others have also successfully used small molecules to pattern BFCNs resulting in efficiencies ranging from 15 up to 80% (Liu et al., 2013b; Yue et al., 2015; Hu et al., 2016; Muñoz et al., 2020). Although the yields of BFCNs are good, the mixed neuronal cultures leave room for improvement in the established BFCN protocols.

The promising strategies to derive BFCNs from PSCs indicates the use of isogenic iPSCs will enable us to define markers of dysfunction, aging, and degeneration in these cells to reveal molecular signatures and signaling pathways underlying BFCN degeneration in DS and DS-AD. One of the many advantages of PSC models is the retention of the human genetic background by establishing patient specific iPSCs (Brazel et al., 2003; Li et al., 2009). However, through the reprogramming process iPSCs lose many of the aging markers of the somatic donor cells (Xu et al., 2005; Gulacsi and Anderson, 2006). The resulting iPSCs also share transcriptional and functional profile similarities to those in fetal development, making it difficult to study age-related diseases. Thus, generating hPSC-derived neurons that mirror those in the adult and aging brain is essential for neurodegenerative disease modeling using hPSCs. Further, the results have the potential to inform our understanding of the vulnerability of BFCNs in DS, AD, PD (Brazel et al., 2003), amyotrophic lateral sclerosis (Li et al., 2009), progressive supranuclear palsy (Xu et al., 2005; Gulacsi and Anderson, 2006), and olivopontocerebellar atrophy (Xu et al., 2010).

**REFERENCES**

Alzheimer's Association (2021). 2021 Alzheimer's disease facts and figures. *Alzheimers Dement.* 17, 327–406. doi: 10.1001/alz.12328

Akeson, E. C., Lambert, J. P., Narayanswami, S., Gardiner, K., Bechtel, I. J., and Davison, M. T. (2001). T65Dn – localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. *Cyto.genet. Cell Genet.* 93, 270–276. doi: 10.1159/000056997

Allred, M. J., Chao, H. M., Lee, S. H., Belin, J., Powers, B. E., Petkova, E., et al. (2018). CA1 pyramidal neuron gene expression mosaics in the T65Dn murine model of Down syndrome and Alzheimer’s disease following maternal choline supplementation. *Hippocampus* 28, 251–268. doi: 10.1002/hipo.22832

Allred, M. J., Chao, H. M., Lee, S. H., Belin, J., Powers, B. E., Petkova, E., et al. (2019). Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the T65Dn mouse model of Down syndrome and Alzheimer’s disease. *FASEB J.* 33, 9871–9884. doi: 10.1096/fj.201802699r

Alonso, A. D., Cohen, L. S., Corbo, C., Morozova, V., Eldrissi, A., Phillips, G., et al. (2018). Hyperphosphorylation of Tau associates with changes in its function beyond microtubule stability. *Front. Cell. Neurosci.* 12:338. doi: 10.3389/fncel.2018.00338

Alonso, A. D., Di Clerico, J., Li, B., Corbo, C. P., Alaniz, M. E., Grundke-Iqbal, I., et al. (2010). Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. *J. Biol. Chem.* 285, 30851–30860. doi: 10.1074/jbc.m110.110957

Alzheimer’s Association (2019). FDA-Approved Treatments for Alzheimer’s. Chicago, IL: Alzheimer’s Association.

Amano, T., Jeffries, E., Amano, M., Ko, A. C., Yu, H., and Ko, M. S. (2015). Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures. *DNA Res.* 22, 331–342. doi: 10.1093/dnares/dsv016

**SUMMARY**

With an increased life expectancy of DS individuals, it is important to study the cellular and molecular mechanisms that underlie neurodegeneration and AD in DS (Sawada et al., 2008; Duncan, 2011; Baker and Petersen, 2018). Here, we have raised the need to address the significant gaps in the understanding of the vulnerability of BFCNs in aging and disease by highlighting the critical role of BFCNs in cognition, the vulnerability of BFCNs in animal models of DS and AD and indications that BFCNs degeneration may be one of the earliest events in AD and DS neuropathology.

**AUTHOR CONTRIBUTIONS**

AB and JM contributed to concept and approach of the review. JM collected and organized the research articles and wrote the first draft of the manuscript. MZ and NW wrote and edited sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

**FUNDING**

This work was supported by funding from UW-Madison, the Wisconsin Alumni Research Foundation, the UW School of Medicine and Public Health from the Wisconsin Partnership Program, and Jérôme Lejeune Foundation to AB. JM was supported by the UW–Madison Biotechnology Training Program (NIH 5 T32 GM135066). This study was supported in part by a core grant to the Waisman Center from the National Institute of Child Health and Human Development (U54 HD090256).

**ACKNOWLEDGMENTS**

The authors thank Karla M. Knobel for assistance with microscopy and Carissa Sirois for her valuable and insightful comments.
Cooper, J. D., Salehi, A., Delcroix, J. D., Howe, C. L., Belichenko, P. V., Chu‐Couzens, J., et al. (2001). Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. U.S.A. 98, 10439–10444. doi: 10.1073/pnas.1812192018

Coppola, J. J., and Disney, A. A. (2018). Is there a canonical cortical circuit for the cholinergic system? Anatomical differences across common model systems. Front. Neural Circuits 12:8. doi: 10.3389/fncir.2018.00008

Coyle, J. T., Price, D. L., and DeLong, M. R. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219, 1184–1190. doi: 10.1126/science.6338589

Fernandez-Cabello, S., Kronbichler, M., Van Dijk, K. R. A., Goodman, J. A., Spreng, R. N., and Schmitz, T. W. (2020). Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. Brain 143:1009.
Handen, B. L., Cohen, A. D., Channamalappa, U., Bulova, P., Cannon, S. A., Cohen, W. I., et al. (2012). Imaging brain amyloid in nondoned young adults with Down syndrome using Pittsburgh compound B. *Alzheimers Dement.*, 8, 496–501. doi: 10.1016/j.jalz.2011.09.029

Handen, B. L., Lott, I. T., Christian, B. T., Schupf, N., O'Byrant, S., Mapstone, M., et al. (2020). The Alzheimer’s biomarker consortium–Down syndrome: rationale and methodology. *Alzheimers Dement.* 12:e21065.

Hansew, B. J., Betensky, R. A., Jacobs, H. I., Schultz, A. P., Sepulcre, J., Becker, J. A., et al. (2019). Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. *JAMA Neurol.* 76, 915–924.

Hardy, J., and Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. *Trends Pharmacol. Sci.* 12, 383–388. doi: 10.1016/0165-6147(91)90609-v

Harkany, T., Hartig, W., Bergbush, P., Dobbszay, M. B., Zilberter, Y., Edwards, R. H., et al. (2003). Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurones. *Eur. J. Neurosci.* 18, 1979–1992. doi: 10.1046/j.1460-9568.2003.02898.x

Hartley, S. L., Handen, B. L., Devenny, D., Tudorascu, D., Piro-Gambetti, B., Zammit, M. D., et al. (2020). Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer’s disease in Down syndrome. *Alzheimers Dement.* 12:e121065.

Hasselmo, M. E. (2006). The role of acetylcholine in learning and memory. *Curr. Opinion Neurobiol.* 16, 710–715. doi: 10.1016/j.conb.2006.09.002

Hattori, M., Fujiyama, A., Taylor, T. D., Watanabe, H., Yada, T., Park, H. S., et al. (2000). The DNA sequence of human chromosome 21. *Nature* 405, 311–319.

Head, E., Lott, I. T., Wilcock, D. M., and Lemere, C. A. (2016). Aging in Down syndrome and the development of Alzheimer’s disease neuropathology. *Curr. Alzheimer Res.* 13, 18–29. doi: 10.2174/15672050126615102114607

Head, E., Powell, D., Gold, B. T., and Schmitt, F. A. (2012). Alzheimer’s disease in Down syndrome. *Eur. J. Neurodegener. Dis.* 1, 353–364.

Hedreen, J. C., Strubbe, R. G., Whitehouse, P. J., and Price, D. L. (1984). Topography of the magnocellular basal forebrain system in human brain. *J. Neuropathol. Exp. Neurol.* 43, 1–21. doi: 10.1002/jn.1840430102

Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. (2013). NLPR3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. *Nature* 493, 674–678. doi: 10.1038/nature11729

Herault, Y., Delabar, J. M., Fisher, E. M. C., Tybulewicz, V. L. J., Yu, E., and Brault, V. (2017). Rodent models in Down syndrome research: impact and future opportunities. *Dis. Models Mech.* 10, 1165–1186. doi: 10.1242/dmm.029728

Heys, J. G., Giocomo, L. M., and Hasselmo, M. E. (2010). Cholinergic modulation of the resonance properties of stellate cells in layer II of medial entorhinal cortex. *J. Neurophysiol.* 104, 258–270. doi: 10.1152/jn.00492.2009

Hibouyi, Y., Grad, I., Letourneau, A., Sailani, M. R., Dalouh, S., Santoni, F. A., et al. (2004). Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monzygotic twins discordant for trisomy 21. *EMBO Mol. Med.* 6, 259–277. doi: 10.1002/emmm.201302848

Holland, A. J., Hon, J., Huppert, F. A., and Stevens, F. (2000). Incidence and course of dementia in people with Down’s syndrome: findings from a population-based study. *J. Intell. Disabil. Res.* 44(Pt 2), 138–146. doi: 10.1046/j.1365-2788.2000.00263.x

Hooli, B., Mohapatra, G., Mattheisen, M., Parrado, A., Roehr, J., Shen, Y., et al. (2012). Role of common and rare APP DNA sequence variants in Alzheimer disease. *Neurology* 78, 1250–1257. doi: 10.1212/wnl.0b013e3182515972

Hovda, D. A., and ery, A. (2012). Protein tau (tau) is a major antigenic component of paired helical filaments in preclinical Alzheimer’s disease. *Nat. Neurosci.* 17, 304–311. doi: 10.1038/nn.3606

Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Salazar, A. M., and Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer’s disease. *Alzheimers Dement.* 4, 575–590.

Kishnani, P. S., Spiridigliozzi, G. A., Keller, J. H., Sullivan, J. A., Doraiswamy, P. M., and Krishnan, K. R. (2001). Donepezil for Down’s syndrome. *Am. J. Psychiatry* 158:143.

Kiss, J., Schwalm, F., and Balazs, R. (1989). Selective retardation of the development of the basal forebrain cholinergic and pontine catecholaminergic nuclei in the brain of trisomy 16 mouse, an animal model of Down’s syndrome. *Brain Res. Dev. Brain Res.* 50, 251–264. doi: 10.1016/0165-3806(89)90201-0

Knell, W. K., Price, J. C., Mathis, C. A., Tiopelas, N. D., Lopresti, B. J., Zilolko, S. K., et al. (2007). Amyloid deposition begins in the striatum of presenlin-1 mutation carriers from two unrelated pedigrees. *J. Neurosci.* 27, 6174–6184. doi: 10.1523/jneurosci.0730-07.2007

Koehler, A. (1896). Handbuch der Gewebelhehe des Menschen. *Nervensystem des Menschen und der Thiere*, 6th Edn, Vol. 2. Leipzig: W. Engelmann.
elevated amyloid-β burden in Down syndrome. *J. Alzheimer Dis.* 61, 631–644. doi: 10.3233/jad-170720

Lejeune, J., Turpin, R., and Gautier, M. (1959). Le mogolisme, premier exemple d’abération autosomique humaine. *Ann. Genet.* 1, 41–49.

Li, L., Chang, K. H., Wang, P. R., Hirata, R. K., Papayannopoulou, T., and Russell, D. W. (2012). Trisomy correction in down syndrome induced pluripotent stem cells. *Cell Stem Cell* 11, 615–619. doi: 10.1016/j.stem.2012.08.004

Li, X. J., Zhang, X., Johnson, M. A., Wang, Z. B., Lavaute, T., and Zhang, S. C. (2009). Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. *Development* 136, 4055–4063. doi: 10.1242/dev.036624

Lin, Z. Y., Yu, T., Morishima, M., Pao, A., LaDuca, J., Conroy, J., et al. (2014). Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. *Nature Rev. Neurosci.* 15, 135ñ147. doi: 10.1038/nrr1886

Lin, S.-C., and Nicolais, M. A. (2008). Neuronal ensemble bursting in the basal forebrain encodes salience irrespective of valence. *Neuron* 59, 138–149. doi: 10.1016/j.neuron.2008.04.031

Lucchesi, S., Spector, L., and Kordower, J. H. (2012). Trisomy correction in down syndrome induced pluripotent stem cells correct learning and memory deficits. *Nat. Biotechnol.* 30, 415ñ420. doi: 10.1038/nbt.2565

Lockrow, J., Prakasham, A., Huang, P., Bimonte-Nelson, H., Sambamurti, K., and Liu, Y., Liu, H., Sauvey, C., Yao, L., Zarnowska, E. D., and Zhang, S. C. (2013a). Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. *Nat. Protocols* 8, 1670–1679. doi: 10.1038/nprot.2013.106

Liu, Y., Weick, J. P., Liu, H., Krenckic, R., Zhang, X., Ma, L., et al. (2013b). Medial ganglionic eminence-like cells derived from human embryonic stem cells. *Nat. Biotechnol.* 31, 440–447. doi: 10.1038/nbt.2565

Liu, T. T., and Head, E. (2019). Dementia in Down syndrome: unique insights for Alzheimer disease research. *Nat. Rev. Neurol.* 15, 135–147. doi: 10.1038/s41582-018-0132-6

Liu, T. T., Head, E., Doran, E., and Busciglio, J. (2006). Beta-amyloid, oxidative stress and Down syndrome. *Curr. Alzheimer Res.* 3, 521–528. doi: 10.2174/156720506779253050

Lu, H. E., Yang, Y. C., Chen, S. M., Su, H. L., Huang, P. C., Tsai, M. S., et al. (2013). Modeling neurogenesis impairment in down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells. *Exp. Cell Res.* 319, 498–505. doi: 10.1016/j.yexcr.2012.09.017

MacLean, G. A., Menne, T. F., Guo, G. J., Sanchez, D. J., Park, I. H., Daley, G. Q., et al. (2012). Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. *Proc. Natl. Acad. Sci. U.S.A.* 109, 17567ñ17572. doi: 10.1073/pnas.1215468109

Mandis, A., Mereu, R. M., Catte, O., Saba, A., Serchisu, L., Costaggiu, D., et al. (2014). Cognitive impairment and age-related vision disorders: their possible relationship and the evaluation of the use of aspirin and statins in a 65 years-and-over Sardinian population. *Front. Aging Neurosci.* 6:309. doi: 10.3389/fnagi.2014.00309

Mattson, M. P., and Magnus, T. (2006). Ageing and neuronal vulnerability. *Nat. Rev. Neurosci.* 7, 278–294. doi: 10.1038/nrn1886

McNaughton, D., Knight, W., Guerreiro, R., Ryan, N., Lowe, J., Poulter, M., et al. (2012). Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. *Neurobiol. Aging* 33, 426.e13–e21.

Meda, L., Cassatella, M. A., Sziendrei, G. I., Otvos, L. Jr., Baron, P., Villalba, M. A., et al. (1995). Activation of microglial cells by beta-amyloid protein and interferon-gamma. *Nature* 374, 647–650.

Menendez, M. (2005). Down syndrome, Alzheimer’s disease and seizures. *Brain Dev.* 27, 246–252.
to long-lasting increases in the number of basal forebrain cholinergic neurons. J. Neurosci. 22, 2409–2418. doi: 10.1523/jneurosci.22-07-02409.2002

Nukina, N., and Ihara, Y. (1986). One of the antigenic determinants of paired helical filaments is related to tau Protein. J. Biochem. 99, 1541–1544. doi: 10.1093/oxfordjournals.jbchem.a135625

Ovchinnikov, D. A., Korn, G., Virshup, L., Wells, C. A., and Wvetang, E. J. (1981). The Impact of APP on Alzheimer-like pathogenesis and gene expression in Down syndrome iPS-derived neurons. Stem Cell Rep. 11, 32–42. doi: 10.1016/j.stemcr.2018.05.004

Papavassiliou, P., York, T. P., Gurson, N., Hill, G., Nicely, L. V., Sundaram, U., et al. (2009). The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am. J. Med. Genet. Part A 149A, 573–583. doi: 10.1002/ajmg.a.32729

Parikh, V., and Sarter, M. (2008). Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity. Ann. N. Y. Acad. Sci. 1129, 225–235. doi: 10.1196/annals.1417.021

Park, I. H., Arora, N., Huo, H., Maherali, N., Ahsfeldt, T., Shimamura, A., et al. (2008a). Disease-specific induced pluripotent stem cells. Cell 134, 875–886.

Park, I. H., Zhao, R., West, J. A., Abuuchi, A., Huo, H., Ince, T. A., et al. (2008b). Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451, 141–146. doi: 10.1038/nature06534

Perez, S. E., Miguel, J. C., He, B., Malek-Ahmadi, M., Abrahamsson, E. E., Ikonomovic, M. D., et al. (2019). Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia. Acta Neuropathol. 137, 413–436. doi: 10.1007/s00401-019-01965-6

Peplinski, M., and Butterfield, D. A. (2012). Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012:724904.

Perry, E. K., Johnson, M., Kerwin, J. M., Piggott, M. A., Court, J. A., Shaw, P. J., et al. (1992). Convergent cholinergic activities in aging and Alzheimer’s disease. Neurobiol. Aging 13, 393–400. doi: 10.1016/0197-4588(92)90113-c

Pipino, C., Mukherjee, S., David, A. L., Blundell, M. P., Shaw, S. W., Sung, P., et al. (2014). Trisomy 21 mid-trimester amniotic fluid induced pluripotent stem cells maintain genetic signatures during reprogramming: implications for disease modeling and cryobanking. Cell. Reprogram. 16, 331–344. doi: 10.1089/cell.2013.0091

Pichers, K. K., Phillips, K. B., Jones, J. L., Robinson, T. E., and Sarter, M. (2017). Diverse roads to relapse: a discriminative cue signaling cocaine availability is more effective in renewing cocaine seeking in goal trackers than sign trackers exhibiting learning and behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 95, 6256–6261. doi: 10.1073/pnas.95.11.6256

Sakurai, T., Nasuga, R., Yamanaka, A., Kawai, H., Tsujino, N., Muraki, Y., et al. (2005). Input of orexin/hypocretin by a genetically encoded neurons revealed tracer in mice. Neuron 46, 297–308. doi: 10.1016/j.neuron.2005.03.010

Salehi, A., Delcroix, J. D., Belenchko, P. V., Zhan, K., Wu, C., Valletta, J. S., et al. (2006). Increased APP expression in a mouse model of Down syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29–42. doi: 10.1016/j.neuron.2006.05.022

Salehi, A., Delcroix, J. D., and Sawa, D. F. (2004). Alzheimer's disease and NGF signaling. J. Neural Transm. 111, 323–345. doi: 10.1007/s00702-009-0991-x

Sanders, N. C., Williams, D. K., and Wenger, G. R. (2009). Does the learning deficit observed under an incremental repeated acquisition schedule of reinforcement in Ts65Dn mice, a model for Down syndrome, change as they age? Behav. Brain Res. 203, 137–142. doi: 10.1016/j.bbr.2009.04.031

Sarter, M., Bruno, J. P., and Givens, B. (2003). Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? Neurobiol. Learn. Mem. 80, 245–256. doi: 10.1016/s1074-7427(03)00070-4

Sawada, M., Sawada, H., and Nagatsu, T. (2008). Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases. Neurogener. Dis. 5, 254–256. doi: 10.1007/s11063-008-0177-y

Saxena, S., and Caroni, P. (2011). Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71, 35–48. doi: 10.1016/j.neuron.2011.06.031

Schmitz, T. W., and Duncan, J. (2018). Normalization and the cholinergic microcircuit: a unified basis for attention. Trends Cogn. Sci. 22, 422–437. doi: 10.1016/j.tics.2018.02.011

Schmitz, T. W., Soreq, H., Tzivion, G., and Spreng, R. N. (2020). Longitudinal basal forebrain degeneration interacts with TREM2/C3 biomarkers of inflammation in presymptomatic Alzheimer's disease. J. Neurosci. 40, 1931–1942. doi: 10.1523/jneurosci.1184-19.2019

Scott, B. S., Becker, L. E., and Petil, T. L. (1983). Neurobiology of Down's syndrome. Prog. Neurobiol. 21, 199–237.

Selkoe, D. J. (1991). The molecular pathology of Alzheimer’s disease. Nature 353, 18–26. doi: 10.1038/3531800a0

Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science 298, 789–791.

Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25years. EMBO Mol. Med. 8, 595–608.
Tao, Y., and Zhang, S. C. (2016). Neural subtype specification from human
β
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al.
Solari, N., and Hangya, B. (2018). Cholinergic modulation of spatial learning,
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J.,
Sussel, L., Marin, O., Kimura, S., and Rubenstein, J. L. (1999). Loss of
Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok,
Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J.,
Shi, Y., Kirwan, P., Smith, J., Mosca, L., et al. (2018). Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Transl. Neurodegener. 7:28.
Tudorascu, D. L., Anderson, S. J., Minhas, D. S., Yu, Z., Comer, D., Lao, P., et al. (2019). Comparison of longitudinal Aβ in nondemented elderly and Down syndrome. Neurobiol. Aging 73, 171–176. doi: 10.1016/j.neurobiolaging.2018.09.030
van Reekum, R., Black, S. E., Conn, D., and Clarke, D. (1997). Cognition-enhancing drugs in dementia: a guide to the near future. Can. J. Psychiatry 42(Suppl. 1), 35s–50s.
Villemagne, V. L., Ataka, S., Mizuno, T., Brooks, W. S., Wada, Y., Kondo, M., et al. (2009). High striatal amyloid β-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 66, 1537–1544.
Visser, F. E., Aldenkamp, A. P., van Hulffen, A. C., Kuilman, M., Overweg, J., and van, W. J. (1997). Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am. J. Ment. Retard. 101, 400–412.
Wang, H. F., and Liu, F. C. (2001). Developmental restriction of the LIM homeodomain transcription factor Islet-1 expression to cholinergic neurons in the rat striatum. Neuroscience 103, 999–1016. doi: 10.1016/s0306-4522(00)01590-x
Weick, J. P., Held, D. L., Bonadurer, G. F., Doers, M. E., Liu, Y., Maguire, C., et al. (2013). Deficits in human trisomy 21 iPS cells and neurons. Proc. Natl. Acad. Sci. U.S.A. 110, 9662–9667. doi: 10.1073/pnas.1216575110
Weinberger, N. M. (2007). Associative representational plasticity in the auditory cortex: a synthesis of two disciplines. Learn. Memory. 14, 1–16. doi: 10.1101/Im.421807
White, K. G., and Ruske, A. C. (2002). Memory deficits in Alzheimer’s disease: the encoding hypothesis and cholinergic function. Psychol. Bull. Rev. 9, 426–437. doi: 10.3758/bf03196301
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., and DeLong, M. R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Am. Neurol. 10, 122–126. doi: 10.1002/ana.4100100203
Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T., and Delon, M. R. (1982). Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237–1239. doi: 10.1126/science.7058341
Wilcock, D. M. (2012). Neuroinflammation in the aging Down syndrome brain; lessons from Alzheimer’s disease. Curr. Gerontol. Geriatr. Res. 2012:170276.
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., et al. (2015). A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 16, 564–574. doi: 10.1038/nrn3983
Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., et al. (2018). Trisomy of human chromosome 21 enhances amyloid-beta deposition independently of an extra copy of APP. Brain 141, 2457–2474. doi: 10.1093/brain/awy159
Woolf, N. J. (1991). Cholinergic systems in mammalian brain and spinal cord. Prog. Neurobiol. 37, 475–524. doi: 10.1016/0301-0082(91)90006-m
Wu, H., Williams, J., and Nathans, J. (2014). Complete morphologies of basal forebrain cholinergic neurons in the mouse. Elife 3:e02444.
Xu, Q., Guo, L., Moore, H., Wadman, Y., Church, S., and Anderson, S. A. (2010). Sonic hedgehog signalling confers ventral telencephalic progenitors with distinct unilateral interneuron fates. Neural Dev. 5, 328–340. doi: 10.1186/1749-8104-5-9
Xu, Q., Tan, M., and Anderson, S. A. (2008). Fate mapping Nkx2.1 lineage cells in the mouse telencephalon. J. Comp. Neurol. 506, 16–29. doi: 10.1002/cne.21529
Xu, Q., Wonders, C. P., and Anderson, S. A. (2003). Sonic hedgehog maintains the identity of cortical interneuron progenitors in the ventral telencephalon. Development 132, 4987–4998. doi: 10.1242/dev.02090
Xu, W., Fang, F., Ding, J., and Wu, C. (2018). Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease. Traffic 19, 253–262. doi: 10.1111/tra.12547
Xu, W., Weissmiller, A. M., White, J. A., Fang, F., Wang, X. Y., Wu, Y. W., et al. (2016). Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J. Clin. Invest. 126, 1815–1833. doi: 10.1172/jci82409
Yan, R., and Vassar, R. (2014). Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 13, 319–329. doi: 10.1016/s1474-4422(13)70276-x
Yankner, B. A., Duffy, L. K., and Kirschner, D. A. (1990). Neurotrophic and neurotrophic effects of amyloid beta-protein – reversal by tachykinin neuropeptides. Science 250, 279–282. doi: 10.1126/science.2218531
Yates, C. M., Simpson, J., Maloney, A. F. J., Gordon, A., and Reid, A. H. (1980). Alzheimer-like cholinergic deficiency in down syndrome. Lancet 2:979. doi: 10.1016/s0140-6736(80)92137-6
Yiannopoulou, K. G., and Papageorgiou, S. G. (2020). Current and future treatments in Alzheimer disease: an update. J. Central Nerv. Syst. Dis. 12:1179573520907397.
Zaborszky, L., Csordas, A., Mosca, K., Kim, J., Gielow, M. R., Vadasz, C., et al. (2015). Neurons in the Basal Forebrain Project to the cortex in a complex topographic organization that reflects corticocortical connectivity patterns: an experimental study based on retrograde tracing and 3D reconstruction. Cereb. Cortex 25, 118–137. doi: 10.1093/cercor/bht210
Zaborszky, L., Rosin, D. L., and Kiss, J. (2004). Alpha-adrenergic receptor (alpha2 A)) is colocalized in basal forebrain cholinergic neurons: a light and electron microscopic double immunolabeling study. J. Neurocytol. 33, 265–276. doi: 10.1023/b:neur.000044188.67442.9d
Zammit, M. D., Laymon, C. M., Betthouser, T. J., Cody, K. A., Tudorascu, D. L., Minhas, D. S., et al. (2020a). Amyloid accumulation in Down syndrome measured with amyloid load. Alzheimers Dement. 12:e12020.
Zammit, M. D., Laymon, C. M., Tudorascu, D. L., Hartley, S. L., Piro-Gambetti, B., Johnson, S. C., et al. (2020b). Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer’s disease except for the putamen. Alzheimers Dement. 12:e12138.
Zhang, K., Fishel Ben Kenan, R., Osakada, Y., Xu, W., Sinit, R. S., Chen, L., et al. (2013). Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J. Neurosci. 33, 7451–7462. doi: 10.1523/jneurosci.4322-12.2013
Zhao, X., and Bhattacharyya, A. (2018). Human models are needed for studying human neurodevelopmental disorders. Am. J. Hum. Genet. 103, 829–857. doi: 10.1016/j.ajhg.2018.10.009
Zhou, Y., Sun, Y., Ma, Q.-H., and Liu, Y. (2018). Alzheimer’s disease: amyloid-based pathogenesis and potential therapies. Cell Stress 2:150. doi: 10.15698/cst2018.07.143
Zigman, W. B., Schupf, N., Sersen, E., and Silverman, W. (1996). Prevalence of Alzheimer-like cholinergic deficiency in down syndrome. J. Clin. Investig. 98, 1588–1595. doi: 10.1172/jci16356.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Martinez, Zammit, West, Christian and Bhattacharyya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.